Nebenwirkungen · Procysbi
PROCYSBI 25 mg gastro-resistant hard capsules PROCYSBI 75 mg gastro-resistant hard capsules · Abschnitt 4.8 · PDF-Seite 7
HOS-215700 · Präparat HOS-155504
For the immediate-release formulation of cysteamine bitartrate, approximately 35% of patients can be expected to experience adverse reactions. These mainly involve the gastrointestinal and central nervous systems. When these reactions appear at the initiation of cysteamine therapy, temporary suspension and gradual reintroduction of treatment may be effective in improving tolerance. In clinical studies with healthy volunteers, the most frequent adverse reactions were very common GI symptoms (16%) and occurred primarily as single episodes that were mild or moderate in severity. The adverse reactions profile for healthy subjects was similar to the adverse reactions profile in patients relative to GI disorders (diarrhoea and abdominal pain).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T17:10:00Z · SHA-256 a18d8edf86ca1da0f1638ebff69dbff22d3dee9cc8c83023938ef05089bf44ca · Passage aff68ff464d2ac3d4c9ee707f398ccbb5804f75df4b3690bb6702f4ea66d5c7d · Zeichen 31–778 im Abschnitt